IFNG and small cell lung carcinoma: However, a series of subsequent trials of recombinant IFN-α or IFN-γ as maintenance therapy in SCLC, in both the limited and extensive stage settings, failed to demonstrate any improvement in progression-free or overall survival (27–30).